Vaginal DNA vaccination against infectious diseases transmitted through the vagina

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 7, 2012, Pages 2340-2353

  Kanazawa, Takanori ^a   Takashima, Yuuki ^a   Okada, Hiroaki ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Cell penetrating peptides; HIV; Menstrual cycle; Needle free injector; Nuclear localization signals; Review; Vaginal DNA vaccine

Indexed keywords

DNA VACCINE;

ANTIGEN PRESENTATION; DENDRITIC CELL; DNA IMMUNIZATION; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; INOCULATION; INTERNALIZATION; MENSTRUAL CYCLE; MITOSIS; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINA MUCOSA; DRUG ADMINISTRATION ROUTE; FEMALE; VAGINA;

HUMAN PAPILLOMAVIRUS;

DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; SEXUALLY TRANSMITTED DISEASES; VACCINES, DNA; VAGINA;

EID: 84867319576     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. AIDS epidemic update: November 2009. "UNAIDS/09.36E/JC1700E".
2. Hirbod T and Broliden K: Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Int Med 262, 44-58 (2007)) (Pubitemid 47000632)
3. Azizi A, Ghunaim H, Diaz-Mitoma F, Mestecky J: Mucosal HIV vaccines: Aholy grail or dud?. Vaccine 28, 4015-4026 (2010))
4. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer ststistics. CA Cancer J Clin 55, 74-108 (2002))
5. Monie A, Tsen SWD, Hung CF, Wu TC: Therapeutic HPV DNA vaccines. Exp Rev Vaccines 8, 1221-1235 (2009))
6. Hoory T, Monie A, Gravitt P, Wu TC: Molecular epidemiology of human papillomavirus. J Formos Med Assoc 107, 198-217 (2008)) (Pubitemid 351618642)
7. Walboomers JM, Jacobs MV, Manas MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19 (1999)) (Pubitemid 29406813)
8. Gardasil prescribing information. Available from: http://www.mwrck.com/ product/usa/pl-circulars/g/gardasil/gar dasil-pi.pdf.
9. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356, 1928-1943 (2007)) (Pubitemid 46740303)
10. Stanley M: Potential mechanisms for HPV vaccineinduced long-term protection. Genecol Oncol 118, 52-57 (2010))
11. Harper DM: Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 110, S11-17 (2008))
12. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI Cole GA, Crowley-Nowick PA: Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188, 916-926 (2003)) (Pubitemid 36530038)
13. Huang CF, Monie A, Weng WH, Wu TC: DNA vaccines for cervical cancer. Am J Transl Res 2, 75-87 (2010))
14. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magil M, Silverman M, Urban RG, Hedley Ml, Beach KJ: ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obset Gynecol 103, 317-326 (2004))
15. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC: A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15, 361-367 (2009))
16. Fuller DH, Loudon P, Schmaljohn C: Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40, 86-97 (2006)) (Pubitemid 44419542)
17. Liu MA, Ulmer JB: Human clinical trials of plasmid DNA vaccines. Adv Genet 55, 25-40 (2005)) (Pubitemid 43580697)
18. Kutzler MA, Weiner DB: DNA vaccines: ready for prime time?. Nat Rev Genet 9, 776-788 (2008))
19. Dunham SP: The application of nucleic acid vaccines in veterinary medicine. Res Vet Sci 73, 9-16 (2002)) (Pubitemid 35174505)
20. Dhama K, Mahendran M, Gupta PK, Rai A: DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commin 32, 341-356 (2008))
21. Tang DC, Devit M, Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992))
22. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, Dewitt CM: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993)) (Pubitemid 23114660)
23. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90, 11578-11482 (1993))
24. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB: Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90, 4156-4160 (1993)) (Pubitemid 23134185)
25. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178, 92-100 (1998)) (Pubitemid 28328080)
26. Minchess M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical traial. Eur Urol 38, 208-217 (2000)) (Pubitemid 30452325)
27. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R: Phase 1 safety and immune response studies of a DNA vaccine encoding hepayiyis B surface antigen delivered by a gene delivery device. Vaccine 17, 2826-2829 (1999)) (Pubitemid 29323008)
28. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL: Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18, 1893-1901 (2999))
29. Ulmer JB, Wahren B, Liu MA: Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 12, 216-222 (2006)) (Pubitemid 43728411)
30. Davidson AH, Traub-Dargatz JL, Rodeheaver RM, Ostlund EN, Pedersen DD, Moorhead RG, Stricklin JB, Dewell RD, Roach SD, Long RE, Albers SJ, Callan RJ, Salman MD: Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J Am Vet Med Assoc 226, 240-245 (2005)) (Pubitemid 40123299)
31. Garver KA, LaPatra SE, Kurath G: Efficacy of an infectious hemoatopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis Aquat Organ 64, 13-22 (2005)) (Pubitemid 40641108)
32. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD: Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24, 4582-4585 (2006)) (Pubitemid 44218845)
33. Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R: Plasmid-mediated growth hormonereleasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J Anim Sci 84, 733-742 (2006)) (Pubitemid 44405688)
34. Stevceva L, Strober W: Mucosal HIV vaccines: Where are we now?. Curr HIV Res 2, 1-10 (2004)) (Pubitemid 38854920)
35. Demberg T, Robert-Guroff M: Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 28, 20-48 (2009))
36. Singh M, Vajdy M, Gardner J, Briones M, O'Hagan D: Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 20, 594-602 (2001)) (Pubitemid 32973805)
37. White HD, Yeaman GR, Givan AL, Wira CR: Mucosal immunity in the human female reproductive tract: cytotoxic T-lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. Am J Reprod Immunol 37, 30-38 (1997)) (Pubitemid 27075966)
38. Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M, Einfeld D, Schwartz RM, King CR, Gall JG, Nabel GJ: Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J virol 83, 7166-7175 (2009))
39. Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group: Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 189, 1221-1231 (2004)) (Pubitemid 38457247)
40. Takamura S, Niikura M, Li TC, Takeda N, Kusagawa S, Takebe Y, Miyamura T, Yasutomi Y: DNA vaccineencapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 11, 628-635 (2004)) (Pubitemid 38455981)
41. Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM: Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20, 1968-1974 (2002)) (Pubitemid 34460483)
42. Akagi T, Kawamura M, Ueno M, Hiraishi K, Adachi M, Serizawa T, Akashi M, Baba M: Mucosal immunization with inactivated HIV-1 capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol 69, 163-172 (2003)) (Pubitemid 36068870)
43. Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M: Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol 73, 368-377 (2004)) (Pubitemid 38685742)
44. Wang X, Uto T, Akagi T, Akashi M, Baba M: Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol 81, 10009-10016 (2007)) (Pubitemid 350067704)
45. Mantis NJ, Kozlowski PA, Mielcarz DW, Weissenhorn W, Neutra MR: Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 19, 3990-4001 (2001)) (Pubitemid 32566324)
46. Eo SK, Gierynska M, Kamar AA, Rouse BT: Primeboost immunization with DNA vaccine: mucosal route of administration changes the rules. J immunol 166, 5473-5479 (2001)) (Pubitemid 32374168)
47. Bruhl P, Kerschbaum A, Eibl MM, Mannhalter JW: Anexperomental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice. AIDS Res Hum Retroviruses 14, 401-407 (1998)) (Pubitemid 28125698)
48. Holmgren J, Czerkinsky C: Mucosal immunity and vaccines. Nat Med 11, S45-53 (2005)) (Pubitemid 40562303)
49. Lagranderie M, Winter N, Balazuc AM, Gicquel B, Gheorghiu M: A cock-tail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retoroviruses 14, 1625-1633 (1998)) (Pubitemid 28563852)
50. Hamajima K, Hoshino Y, Xin KQ, Hayashi F, Tadokoro K, Okuda K: Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin Immunol 102, 12-18 (2002)) (Pubitemid 34095219)
51. Wang SW, Bertley FM, Kozlowski PA, Herrmann L, Manson K, Mazzara G, Piatak M, Johnson RP, Carville A, Mansfield K, Aldovini A: An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 20, 846-859 (2004)) (Pubitemid 39121205)
52. Lindenburg CE, Stolte I, Langendam MW, Miedema F, Williams IG, Colebunders R, Weber JN, Fisher M, Coutinho RA: Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24: Ty virus-like particles on HIV-1 disease progession. Vaccine 20, 1343-2347 (2002))
53. Cole AM: Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 306, 199-230 (2006)) (Pubitemid 47400323)
54. Parr EL and Parr MB: A comparison of antibody titers in mouse uterine fluid after immunization by several routes, and effect of the uterus on antibody titers in vaginal fluid. J Reprod Fetrtil 89, 619-625 (1990)) (Pubitemid 20238678)
55. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP: Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 65, 1387-1394 (1997)) (Pubitemid 27146629)
56. Kato H, Bukawa H, Hagiwara E, Xin KQ, Hamajima K, Kawamoto S, Sugiyama M, Sugiyama M, Noda E, Nishizaki M, Okuda K: Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine 18, 1151-1160 (2000)) (Pubitemid 30001828)
57. Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, Cranage M, Malcolm RK, Shattock RJ, Woolfson AD: Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 27, 6791-6798 (2009))
58. Shacklett BL: Cell-mediated immunity to HIV in the female reproductive tract. J Reprod Immunol 83, 190-195 (2009))
59. Kozlowski PA and Neutra MR: The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 3, 217-228 (2003)) (Pubitemid 36443221)
60. Albu DI, Jones-Trower A, Woron AM, Stellerecht K, Broder CC, Metzger DW: Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type I glycoproteins. J Virol 77, 5589-5597 (2003)) (Pubitemid 36538951)
61. Marinaro M, Riccomi A, Rappuoli R Pizza M, Fiorelli V, Tripiciano A, Cafaro A, Ensoli B, De Magistris MT: Mucosal delivery of human immunodeficiency virus-1 Tat protein in mice slicits systemic neutralizing antibodies cytotoxic T lymphocytes and mucosal IgA. Vaccine 21, 3972-3981 (2003)) (Pubitemid 37338225)
62. Devito C, Zubuer B, Schröder U, Benthin R, Okuda K, Broliden K, Wahren B, Hinkula J: Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173, 7078-7089 (2004)
63. Bergmeier LA, Lehner T: Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 19, 21-28 (2006))
64. Zhao X, Deak E, Soderberg K, Linehan M, Spezzano D, Zhu J, Knipe DM, Iwasaki A: Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 197, 153-162 (2003)) (Pubitemid 36152310)
65. Baker DA and Plotkin SA: Enhancement of vaginal infection in mice by herpes simplex virus type II with progesterone. Proc Soc Exp Biol Med 158, 131-134 (1978)) (Pubitemid 8386573)
66. Gallichan WS and Rosenthal KL: Effects of the estrous cysle on local humoral immune responses and protection of intranasally immunized female genital tract. Virolgy 224, 487-497 (1996)) (Pubitemid 26364496)
67. Overall JC, Kern ER, Schlitzer RL, Friedman SB, Glasgow LA: Genital herpesvirus hominis infection in mice. I. Development of an experimental model. Infect Immun 11, 476-480 (1975))
68. Parr MB, Kepple L, Mcdermott MR, Drew MD, Bozzola JJ, Parr EL: Amouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus typee 2. Lab Invest 70, 369-380 (1994)) (Pubitemid 24116531)
69. Kanazawa T, Takashima Y, Hirayama S, Okada H: Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine. Int J Pharm 360, 164-170 (2008))
70. Wira CR and Rossoll RM: Antigen-presenting cells in the female reproductive tract: influence of sex hormones on antigen presentation in the vagina. Immunology 84, 505-508 (1995))
71. Parr MB and Parr EL: Antigen recognition in the female reproductive tract. 1. Uptake of intraluminal protein tracers in the mouse vagina. J Reprod Immunol 17, 101-114 (1990)) (Pubitemid 20101933)
72. Levine MM and Campbell JD: Mucosal immunization and needle-free injection devices, in: Levine MM, Kaper, JB, Rappuoli R, Liu MA, Good MF, (Ed.), New Generation Vaccines, Marcel Dekker, Inc., New York, pp. 393-399 (2004))
73. McGhee JR and Kiyono H: New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis 2, 55-73 (1993)) (Pubitemid 23252451)
74. Jain L, Barone KS, Flanagan MP, Michael JG: Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen. Vaccine 14, 42-48 (1996)) (Pubitemid 26043131)
75. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA: A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 178, 7211-7221 (2007)) (Pubitemid 46847447)
76. Wassen L, Schön K, Holmgren J, Jertborn M, Lycke N: Local intravaginal vaccination of the female genital tract. Scand J Immunol 44, 408-414 (1996)) (Pubitemid 26327025)
77. Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT: Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbs Infect 5, 571-578 (2003)) (Pubitemid 36645117)
78. Oh YK, Park JS, Yoon H, Kim CK: Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine 21, 1980-1988 (2003))
79. Kanazawa T, Takashima Y, Shibata Y, Tsuchiya M, Tamura T, Okada H: Effective vaginal DNA delivery with high transfection efficiency is a good system for induction of higher local vaginal immune responses. J Pharm Pharmacol 61, 1457-1463 (2009))
80. Codon C, Watkins SC, Celluzzi CM, Thompson K, Falo LDJr: DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2, 1122-1128 (1996)) (Pubitemid 26338632)
81. Haneberg B, Kendall D, Amerongen HM, Apter FM, Kraehenbuhl JP, Neutra MR: Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun 62, 15-23 (1994)) (Pubitemid 24011934)
82. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR: Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169, 566-574 (2002)) (Pubitemid 34686180)
83. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J: Induction of antitumor immunity by vaccination of dendritic cells transfected with MUCI RNA. J immunol 165, 5713-5719 (2000))
84. Rughetti A, Biffoni M, Sabbatucci M, Rahimi H, Pellicciotta I, Fattorossi A, Pierelli L, Scambia G, Lavitrano M, Frati L, Nuti M: Transfected human dendritic cells to induce antitumor immunity. Gene Ther 7, 1458-1466 (2000))
85. Landi A, Babiuk LA, van Drunen Little-van den Hurk S: High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukocyte Biol 82, 849-860 (2007)) (Pubitemid 47511045)
86. Yang Z, Sahay G, Sriadibhatla S, Kabanov AV: Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjugate Chem 19, 1987-1994 (2008))
87. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, Harashima H, Sugiura Y: Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12, 1005-1011 (2001)) (Pubitemid 33136872)
88. Tanaka K, Kanazawa T, Shibata Y, Fukuda T, Takashima Y, Okada H: Development of cell-penetrating peptide-modified MPEG-PCL diblock copolymeric nanoparticles for systemic gene delivery. Int J Pharm 396, 229-238 (2010))
89. Nakase I, Hirose H, Tanaka G, Tadokoro A, Kobayashi S, Takeuchi T, Futaki S: Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis. Mol Ther 17, 1868-1876 (2009))
90. Sawant R, Torchilin V: Intracellular Delivery of Nanoparticles with CPPs. Methods Mol Biol 683, 431-451 (2011))
91. Collins E, Birchall JC, Williams JL, Gumbleton M: Nuclear localisation and pDNA condensation in non-viral gene delivery. J Gene Med 9, 265-274 (2007)) (Pubitemid 46746317)
92. Pouton C, Wagstaff KM, Roth DM, Moseley GW, Jans D: Targeted delivery to the nucleus. Adv Drug Deliv Rev 59, 698-717 (2007)) (Pubitemid 47320817)
93. van der Aa M, Mastrobattista E, Oosting RS, Hennink WE, Koning GA, Crommelin D: The Nuclear Pore Complex: The Gateway to Successful Nonviral Gene Delivery. Pharm Res 23, 447-459 (2006))
94. Subramanian A, Ranganathan P, Diamond SL: Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat Biotechnol 17, 873-7 (1999)) (Pubitemid 29416660)
95. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y: Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276, 5836-5840 (2001))
96. Morris MC, Depollier J, Mery J, Heitz F, Divita G: A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19, 1173-1176 (2001)) (Pubitemid 33115705)
97. Schewarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (1999)) (Pubitemid 29420581)
98. Boulanger P, Di Giorgio C, Vierling P: Synthesis of acridine-nuclear localization signals (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur J Med Chem 40, 1295-1306 (2005)) (Pubitemid 41618270)
99. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270, 18997-19007 (1995))
100. Ohno M, Fornerod M, Mattaj IW: Nucleocytoplasmic transport: the last 200 nanometers. Cell 92, 327-336 (1998)) (Pubitemid 28093011)
101. Xu L, Massague J: Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol 5, 209-219 (2004)) (Pubitemid 38325802)
102. Fagerlund R, Kinnunen L, Köhler M, Julkunen I, Melen K: NF-κB is transported into the nucleus by importin a3 and importin a4. J Biol Chem 280, 15942-15951 (2005))
103. Kanazawa T, Takashima Y, Murakoshi M, Nakai Y, Okada H: Enhancement of gene transfection into human dendritic cells using cationic PLGA nanospheres with synthesized nuclear localization signal. Int J Pharm 379, 187-195 (2009))
104. Kutteh WH, Edwards RP, Menge AC, Mestecky J: IgA immunity in female reproductive tract secretions. In Griffin PD, Johnson PM (cds). Local immunity in reproductive tract tissures. Oxford University Press New Delhi India 229-243 (1993))
105. Cui Z, Baizer L, Mumper RJ: Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 102, 105-115 (2003)) (Pubitemid 36412155)
106. Haensler J, Verdelet C, Sanchez V, Girerd-Chambaz Y, Bonnin A, Trannoy E, Krishnan S, Meulien P: Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 17, 628-638 (1999)) (Pubitemid 29074715)
107. Ren S, Li M, Smith JM, DeTolla LJ, Furth PA: Lowvolume jet injection for intradermal immunization in rabbits. BMC Biotech 2, 10 (2002))
108. Aquiar JC, Hedstrom RC, Rogers WO, Charoenvit Y, Sacci JB, Lanar DE, Majam VF, Stout RR, Hoffman SL: Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 20, 275-280 (2002))
109. Anwer K, Earle KA, Shi M, Wang J, Munper RJ, Proctor B, Jansa K, Ledebur HC, Davis S, Eaglstein W, Rolland AP: Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res 16, 889-895 (1999)) (Pubitemid 29284201)
110. Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, Gorse G.J, Newman FK, Yu O, Weniger BG: Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19, 4703-4709 (2001)) (Pubitemid 32800754)
111. Mumper RJ and Cui Z: Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 31, 255-262 (2003)) (Pubitemid 37162798)
112. Kanazawa T, Takashima Y, Tamura T, Tsuchiya M, Shibata Y, Udagawa H, Okada H: Local gene expression and immune responses of vaginal DNA vaccination using needle-free injector. Int J Pharm 396, 11-16 (2010))
113. Giudice EL and Campbell, J.D: Needle-free vaccine delivery. Adv Drug Deliv Rev 58, 68-89 (2006))
114. Tanaka K, Kanazawa T, Ogawa T, Takashima Y, Fukuda T, Okada H: Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing. Int J Pharm 398, 229-238 (2010))
115. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 13, 856-861 (2010))
116. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T: Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood in presss